Cagrilintide
Cagrilintide
Research Use Only and not for human consumption. Bionk Peptides delivers high-performance research compounds engineered with uncompromising attention to detail. Every vial is produced to exceed 99% purity and supplied in lyophilised powder form, preserving molecular integrity while ensuring optimal stability and precision in application. Bionk Peptides are commitment to elevated research performance.
Couldn't load pickup availability
Description
Cagrilintide
Cagrilintide is a long-acting amylin analogue, developed by Novo Nordisk, that demonstrates significant weight loss, improved blood sugar control, and reduction in waist circumference. It is highly effective on its own and, when paired with semaglutide (forming CagriSema), it shows enhanced, potentially industry-leading results. It offers a weekly injection format that reduces appetite, delays gastric emptying, and improves cardiometabolic markers.
- Significant Weight Loss:
Trials have shown that Cagrilintide 2.4 mg can lead to a roughly 9.7% to 11% reduction in body weight over 26–68 weeks. -
Cardiometabolic Improvements:
Beyond weight loss, studies have shown improvements in systolic blood pressure, lipid profiles, and reduced inflammation markers (C-reactive protein). -
Improved Glycemic Control:
It has shown to be effective in reducing HbA1c levels, particularly in individuals with type 2 diabetes, with some studies showing an 87.7% reversal of prediabetes to normoglycemia. -
Reduced Appetite:
It acts as a long-acting amylin analog, which reduces hunger and increases the feeling of fullness. - Weekly Convenience:
Its stable, long-acting formula allows for once-weekly dosing.
